If you are searching for investments to supercharge your portfolio, then it could be worth checking out the ASX stock in this article.
That's because analysts at Bell Potter think it could almost double in value over the next 12 months.
Image source: Getty Images
Which ASX stock?
The stock that Bell Potter is bullish on is EBR Systems Inc (ASX: EBR).
It is a clinical stage medical device company that has developed its patented Wireless Stimulation Endocardially (WiSE) technology for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation therapy.
Bell Potter highlights that the ASX stock has recently made a big step towards the commercial launch of WiSE. It said:
EBR recently cleared the final hurdle in its path toward a successful commercial launch with CMS approval of WiSE under the New Technology Add-On Payment scheme for Medicare inpatients (NTAP). CMS has also recommended approval for the payment scheme in the outpatient setting (TPT or Transition Pass-Through).
In light of this, the broker notes that the company is now busy training its team to assist hospitals with NTAP and TPT. It adds:
It's one thing to have reimbursement, and another to ensure hospital customers administer coding and billing effectively to facilitate hospitals and doctors being paid correctly and promptly. EBR is training its team to assist hospitals in this regard so that hospitals are paid by Medicare within 90 days. EBR should be paid within 30 days.
All in all, Bell Potter believes the ASX stock is well-positioned to start generating revenue in the near future. It is forecasting revenue of US$19.8 million in FY 2026 and then US$83.7 million in FY 2027.
Big returns
According to the note, the broker has retained its buy rating and $2.25 price target on the ASX stock. Based on its current share price of $1.17, this implies potential upside of 92% for investors over the next 12 months.
To put that into context, a $5,000 investment would be worth over $9,000 by this time next year if Bell Potter is on the money with its recommendation. It concludes:
Early adopter usage and momentum behind leadless pacing technology, provides an exciting back drop to the start of the commercial launch of the WiSE system. Given a number of procedures have occurred in the pre-reimbursement environment, news flow re utilisation momentum in the first quarter of reimbursement should be a positive catalyst to support the share price.
